May 21 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O:
TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 OASIS STUDY OF TNX-102 SL FOR REDUCTION OF ACUTE STRESS REACTION
TONIX PHARMACEUTICALS HOLDING CORP - TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026
Source text: ID:nGNX9gmZXX
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.